Technology Gap in Pediatric Therapeutics
Children respond differently to therapies for patients of age, yet off-label prescriptions remain widespread.
Every year, adverse drug reactions account for €1.3 billion cost per country. In children, the incidence is 4x higher, and most reactions are serious.
While European initiatives are steadily improving pediatric trial design, trustworthy AI tools tailored to children's pharmacological profiles are still missing.
Proactive Pediatric Safety through Predictive AI Modeling
To enhance pediatric trial design and safeguard young patients, we are developing an intelligence engine that predicts adverse drug reactions in children.
If early access aligns with your goals, let us know! We welcome urgency in bringing this breakthrough forward.
